Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study-Reference-Cited by-同舟云学术

Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study

Published:2023-11 Issue:11 Volume:24 Page:1229-1241
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Pan Jing,Tang Kaiting,Luo Yuechen,Seery Samuel,Tan Yue,Deng Biping,Liu Feng,Xu Xiuwen,Ling Zhuojun,Song Weiliang,Xu Jinlong,Duan Jiajia,Wang Zelin,Li Chunyu,Wang Kai,Zhang Yibing,Yu Xinjian,Zheng Qinlong,Zhao Liping,Zhang Jiecheng,Chang Alex H,Feng Xiaoming

Publisher

Elsevier BV

Subject

Oncology

Reference30 articles.

1. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia;Maude;N Engl J Med,2018

2. Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL;Shah;J Clin Oncol,2021

3. High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients;Pan;Leukemia,2017

4. CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia;Pan;Leukemia,2019

5. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study;Shah;Lancet,2021

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Revolutionizing Cancer Treatments through Stem Cell-Derived CAR T Cells for Immunotherapy: Opening New Horizons for the Future of Oncology;Cells;2024-09-10

2. Les cellules CAR-T ont-elles tenu leurs promesses dans le traitement des leucémies aiguës en 2024 ?;Bulletin de l'Académie Nationale de Médecine;2024-08

3. A bibliometric and knowledge-map study on the treatment of hematological malignancies with CAR-T cells from 2012 to 2023;Human Vaccines & Immunotherapeutics;2024-07-03

4. Overcoming the challenges of primary resistance and relapse after CAR-T cell therapy;Expert Review of Clinical Immunology;2024-05-14

5. Newer generations of multi-target CAR and STAb-T immunotherapeutics: NEXT CART Consortium as a cooperative effort to overcome current limitations;Frontiers in Immunology;2024-05-08